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Protocol
AbstrACt
Introduction Chronic obstructive pulmonary disease 
(COPD) is a progressive disease affecting 3 million people 
in the UK, in which patients exhibit airflow obstruction 
that is not fully reversible. COPD treatment guidelines are 
largely informed by randomised controlled trial results, 
but it is unclear if these findings apply to large patient 
populations not studied in trials. Non-interventional 
studies could be used to study patient groups excluded 
from trials, but the use of these studies to estimate 
treatment effectiveness is in its infancy. In this study, we 
will use individual trial data to validate non-interventional 
methods for assessing COPD treatment effectiveness, 
before applying these methods to the analysis of treatment 
effectiveness within people excluded from, or under-
represented in COPD trials.
Methods and analysis Using individual patient data 
from the landmark COPD Towards a Revolution in COPD 
Health (TORCH) trial and validated methods for detecting 
COPD and exacerbations in routinely collected primary 
care data, we will assemble a cohort in the UK Clinical 
Practice Research Datalink (selecting people between 
1 January 2004 and 1 January 2017) with similar 
characteristics to TORCH participants and test whether 
non-interventional data can generate comparable results 
to trials, using cohort methodology with propensity score 
techniques to adjust for potential confounding. We will 
then use the methodological template we have developed 
to determine risks and benefits of COPD treatments in 
people excluded from TORCH. Outcomes are pneumonia, 
COPD exacerbation, mortality and time to treatment 
change. Groups to be studied include the elderly (>80 
years), people with substantial comorbidity, people with 
and without underlying cardiovascular disease and people 
with mild COPD.
Ethics and dissemination Ethical approval has been 
granted by the London School of Hygiene & Tropical 
Medicine Ethics Committee (Ref: 11997). The study has 
been approved by the Independent Scientific Advisory 
Committee of the UK Medicines and Healthcare Products 
Regulatory Agency (protocol no. 17_114R). An application 
to use the TORCH trial data made to  cli nica lstu dyda tare 
quest. com has been approved. In addition to scientific 
publications, dissemination methods will be developed 
based on discussions with patient groups with COPD.
IntroduCtIon 
background and rationale
Chronic obstructive pulmonary disease 
(COPD) affects 3 million people in the UK.1 
The most common cause is smoking, and 
patients exhibit airflow obstruction that is 
not fully reversible. The disease is progres-
sive, with declining lung function and a wors-
ening of symptoms. Most troublesome are 
acute exacerbations manifested as a sudden 
worsening of symptoms, for example, severe 
coughing, shortness of breath and chest 
congestion, requiring urgent treatment and 
possibly hospitalisation. While smoking cessa-
tion remains the most effective intervention, 
the rate of exacerbation can be reduced by 
regular medication such as combination 
of long-acting beta-agonists (LABA) and 
strengths and limitations of this study
 ► Large cohort study.
 ► Use of validated methods for detecting chronic 
obstructive pulmonary disease (COPD) within the 
Clinical Practice Research Datatlink.
 ► Use of randomised controlled trial (RCT) individual 
patient data to assess ability of non-interventional 
methods to detect COPD treatment effects within an 
RCT-analagous population.
 ► Adherence to medication will need to be assessed 
based on proxy variables (eg, time covered by 
prescription).
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inhaled corticosteroids (ICS) or long-acting muscarinic 
antagonists (LAMAs).2 3 
COPD treatment guidelines are largely informed by 
randomised controlled trial (RCT) results,4 but it is not 
clear if these findings apply to large patient populations 
not studied in trials. Fluticasone propionate+salmeterol 
(FP/SAL) is a LABA/ICS combination and is one of the 
most widely used COPD treatments. It was studied in 
large randomised trials (eg, the TORCH trial),2 but the 
effects of treatment in important patient groups who 
were not studied are unknown. Some were excluded from 
trials (eg, those aged >80 years and those with substan-
tial comorbidity) while others are under-represented (eg, 
people with mild COPD),2 5 meaning conclusions about 
these groups are difficult to make.
While the conduct of non-interventional studies (some-
times also referred to as ‘observational studies’) to inves-
tigate possible drug harms is well established, the use of 
these studies to estimate treatment effectiveness is in its 
infancy. Issues of treatment channelling and indication 
bias mean that measuring the intended benefit of a treat-
ment is beset with difficulties. Over the next few years, we 
will see more non-interventional studies of drug effective-
ness emerging due to recent legislation requiring phar-
maceutical companies to study the real-world effects of 
medications6 7; however, rigorous, validated methodology 
is needed to translate these complex data into reliable 
evidence. For example, the availability of anonymised 
individual patient data from RCTs provides the potential 
for ‘RCT-analogous’ cohorts to be selected from non-in-
terventional data sources (by matching patient records 
from non-interventional data to the RCT patient records 
on key characteristics). If subsequent analysis of a non-in-
terventional RCT-analogous cohort generates results that 
are similar to those generated by the reference RCT, one 
could be confident in the validity of the results, and in the 
non-interventional methods used to obtain these results 
in this setting.
In this study, we will use TORCH2 individual trial data 
to validate non-interventional methods for assessing 
COPD treatment effectiveness, before going on to apply 
these methods to the analysis of treatment effectiveness 
within people excluded from or under-represented in the 
TORCH trial. Non-interventional data will be obtained 
from the UK Clinical Practice Research Datalink (linked 
to the Hospital Episodes Statistics database).8 The results 
we generate will aid patients, prescribers and policy 
makers in deciding the most appropriate treatment 
for COPD for all types of patients. The approach used 
can also provide a template for treatment effectiveness 
research using non-interventional data with inbuilt vali-
dation against a randomised trial.
AIMs And objECtIvEs
The aims of our study are (1) to measure the associa-
tion between treatments for COPD and a number of 
COPD outcomes including exacerbation rate, mortality, 
pneumonia and time to treatment change among patients 
not included in randomised clinical trials for COPD 
treatments and (2) to develop a methodological frame-
work with in-built validation against RCT data, for using 
non-interventional electronic health records (EHR) to 
answer questions about drug treatment effects (ie, both 
benefits and risks).
Specific objectives are to: (1) validate methods for 
measuring COPD medication effectiveness in EHR 
data by comparing with trial results; (2) use EHR data 
to measure COPD medication effectiveness in patients 
excluded from trials (most importantly those aged >80 
years or with substantial comorbidity) and (3) determine 
COPD treatment effectiveness in an understudied disease 
stage (mild COPD).
MEthods And AnAlysIs
Figure 1 provides a high-level overview of the study, 
detailing each objective and data source used, and 
showing how existing RCT data will be used in objective 
1 in order to validate methods for analysing COPD in 
routinely collected electronic health data that will then 
be applied to unanswered questions in objectives 2 and 3.
study design
We have chosen a cohort study design as it will allow us to 
measure the effects of prescribing different treatments for 
COPD on future outcomes in different types of patients. 
Eligibility criteria for cohort entry will vary between objec-
tives (detailed in the 'Selection of participants' section).
setting/data sources
Patient data used in this study will be obtained from two 
different sources: the TORCH randomised trial and the 
UK Clinical Practices Research Datalink (CPRD) (linked 
to Hospital Episodes Statistics (HES) data).
torCh
TORCH was a placebo-controlled randomised trial of 
the combined inhaler FP/SAL for the treatment of 
COPD, published in 2007. Patients were randomised to 
receive FP/SAL, FP alone, SAL alone or placebo and 
the primary comparison of interest was between FP/SAL 
and placebo.2 Key outcomes were expected benefits (rate 
of COPD exacerbation and mortality) and an expected 
harm due to the immunosuppressive action of the cortico-
steroid FP (pneumonia). While findings for the primary 
end point of mortality were null, this was thought to be 
due to poor statistical power as a result of a lower than 
anticipated mortality rate. Nonetheless, a lower rate of 
exacerbations was seen with FP/SAL, and a higher rate 
of pneumonia was observed. As one of the largest trials in 
COPD, and with 3-year follow-up, TORCH is a landmark 
study, providing a validation point for our study. We will 
obtain individual patient data from the TORCH study via 
www. clinica lstu dyda tare ques t. com for use in objective 1 
(see the 'Selection of participants' section).
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uK  Clinical Practices research datalink
The CPRD is a very large database of prospectively 
collected, anonymised UK population-based elec-
tronic health records. CPRD primary care records 
comprise ~8%–10% of the UK population and contain 
comprehensive information on clinical diagnoses, 
prescribing, referrals, tests and demographic/lifestyle 
factors.8 In order to contribute to the database, general 
practices and other health centres must meet prespec-
ified standards for research-quality data (ie, be ‘up to 
standard’). Data quality/validity are therefore high and 
the data are nationally representative.8 9 A patient starts 
contributing follow-up time to the database at the date 
they join an ‘up-to-standard’ practice (or the date that 
their practice starts contributing up-to-standard data), 
and stop contributing follow-up time on either their 
death date, their transfer out date (the date that they 
leave the database due to reasons other than death) or 
on the last collection date for their practice. Linkage 
between the primary care records in CPRD and HES 
is well established for >60% of practices in the CPRD, 
providing a data set augmented with detailed secondary 
care diagnostic and procedural records. Algorithms 
have been established to identify COPD, COPD exac-
erbations and pneumonia (both hospital and primary 
care managed) in CPRD/HES-linked data (including 
validated algorithms for COPD and exacerbations).10–12 
See online supplementary material for a high-level 
overview of these algorithms.
selection of participants
Participants will be selected from the CPRD between 1 
January 2004 and 1 January 2017. All patients will need to 
have been registered with an up-to-standard practice for 
Figure 1 Overview of study objectives and sources of data for the chronic obstructive pulmonary disease (COPD) real-
world medicines effects study (RCT, randomised controlled trial, CPRD, the UK Clinical Practice Research Datalink, FP/
SAL, fluticasone propionate+salmeterol). (A) Work performed by others prior to this study. Of the total population of people 
with COPD, only a subset are included in RCTs of COPD treatments, based on the RCT inclusion/exclusion criteria. The RCT 
generates results that inform clinical practice, and the anonymised raw data for the study can be made available to other 
researchers via the Clinical Study Data Request website. For this study, the specific COPD treatment RCT of interest is the 
TORCH trial,2 investigating the effect of FP/SAL on COPD exacerbations. (B) Work to be performed as part of this study. (1) 
Objective 1: a cohort of TORCH (RCT)-analogous patients will be selected from the CPRD, by matching people with COPD 
within CPRD to the records of people included in the trial. An analysis of the effect of FP/SAL on COPD exacerbations will 
then be performed on this TORCH-analagous CPRD cohort. If the results obtained are comparable to those obtained in the 
TORCH trial itself, this will serve as a validation step, showing that data from the non-inverventional (‘real-world’) CPRD source 
can reliably be used to study COPD treatment effects. (2) Objective 2: the validated analysis techniques used for objective 1 
will then be used to study people in CPRD who would not have been eligible for inclusion in an RCT due to their age and the 
presence of other comorbidities, and for whom the effect of FP/SAL is currently unknown. (3) Objective 3: the validated analysis 
techniques will then be used to study people with mild COPD only, who have been under-represented in RCTs, and for whom 
the effect of COPD treatments is unclear.
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at least 12 months. Participant selection criteria will then 
vary by objective as detailed below.
Objective 1: validation of non-interventional methods by comparing 
with trial results
An overview of each of the steps for participant selection 
for objective 1 is provided in figure 2.
Step 1
We will select all patients in the CPRD with COPD who are 
eligible for HES-linkage and during the period covered 
by the linkage would have met the following TORCH 
study inclusion criteria:
 ► a diagnosis of COPD;
 ► age 40–80 years;
 ► smoking history;
 ► lung function (forced expiratory volume in 1 s 
(FEV1) <60% predicted, FEV1/forced vital capacity 
(FVC) ratio <70%).
An eligible-for-inclusion date will then be assigned as 
the date that all of the above inclusion criteria were met 
for the individual. We will then exclude any individual 
Figure 2 Flow chart illustrating the planned selection of CPRD participants for objective 1 of the COPD real-world medicines 
effects study. Note in relation to step 5 (n~18 000) compared with step 1 (n~13 000): approximately 90% of the treated patients 
will also have been eligible as untreated patients, as they did not receive FP/SAL on their TORCH-eligibility date. This means 
that they will have at least one period of time during which they are untreated-eligible but then did subsequently go on to 
receive FP/SAL (meaning they have at least one period of time during which they are treated-eligible). If a person is included as 
both a treated and untreated participant, they will be contributing different periods of their person-time to each cohort (pre-FP/
SAL treatment for the untreated vs post-FP/SAL treatment for treated), and this is handled in the analysis by assigning different 
index dates. COPD, chronic obstructive pulmonary disease; CPRD, UK Clinical Practice Research Datalink;  FP/SAL, fluticasone 
propionate+salmeterol. 
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who has any of the following TORCH study exclusion 
criteria prior to their eligible-for-inclusion date:
 ► a diagnosis of asthma (within the previous 5 years);
 ► a diagnosis for any (non-COPD) respiratory disorder;
 ► a record of lung surgery;
 ► a diagnosis of alpha-1 antitrypsin deficiency;
 ► evidence of drug or alcohol abuse;
 ► a record of having received long-term oxygen therapy;
 ► diagnoses for conditions likely to interfere with the 
TORCH trial or cause death within 3 years;
 ► current use of oral corticosteroid therapy (defined as 
continuous use for >6 weeks, with courses of oral corti-
costeroids separated by a period of <7 days considered 
as continuous use);
 ► any exposure to FP/SAL within the previous 4 weeks.
Finally, in-line with the TORCH trial approach, anyone 
who has an exacerbation requiring oral corticosteroid 
therapy or hospitalisation during the run-in period (the 
2-week period following eligibility) will also be excluded.
Feasibility counts in the CPRD indicate there 
are ~13 000 patients meeting these criteria (figure 2). 
Given the limited information on how asthma exclu-
sions were applied in the TORCH study, we will perform 
a sensitivity analysis in which the asthma exclusion is a 
diagnosis within the previous 1 year, rather than 5 years as 
specified above.
Step 2
Next we will determine if/when these patients ever 
received FP/SAL. During any time between attaining 
TORCH eligibility and a subsequent prescription 
for FP/SAL, patients will be eligible for inclusion 
as an unexposed (to FP/SAL) patient in objec-
tive 1. There may be multiple time periods within 
a person’s record where eligibility as an unexposed 
patient is met (figure 3). Feasibility work shows that 
between 1 January 2004 and 1 January 2017 there 
were ~11 000 TORCH-eligible patients in CPRD who 
did not receive FP/SAL at the time they attained 
TORCH eligibility and therefore have at least one 
time period that means they are eligible for inclusion 
as an objective 1 unexposed participant (figure 2). 
Individuals in CPRD who have more than one unex-
posed eligibility period within their record (figure 3) 
will be able to contribute more than once to the pool 
of unexposed participants (with the covariates and 
person-time contributed unique to the specific unex-
posed eligibility period).
Figure 3 Example timeline for a person in CPRD who is eligible for participation in objective 1, illustrating multiple periods of 
unexposed/exposed (FL/SAL untreated/treated) eligibility. (1) First date of study eligibility: person meets TORCH eligibility as 
detailed in objective 1, step 1 on this date that is, has a diagnosis of COPD, is between 0 and 80 years, FEV1 <60% predicted 
and FEV1/FVC ratio <70%, smoking history, no asthma history, no lung surgery history, no long-term O2 therapy, no alpha-1 
antitrypsin deficiency, no drug/alcohol abuse, no exposure to FP/SAL within the previous 4 weeks. (2) Eligible to enter study as 
an untreated participant: patient can be selected as an untreated participant on any date within this period (as detailed in step 
2). (3) Eligible to enter study as a treated participant: FP/SAL treatment starts, patient is able to be selected as a treated study 
participant on the date that FP/SAL treatment starts (as detailed in step 4). (4) Eligible to enter study as an untreated participant: 
patient stops treatment, but is not immediately eligible for selection again as an untreated study participant. After 4 weeks of no 
FP/SAL treatment however, they meet the TORCH eligibility ciriteria, and may be selected at any date during the remaining one 
untreated week as an untreated patient. This is the second untreated period that this person can contribute to the total pool of 
untreated period records that will be available for matching to the TORCH participants (as detailed in steps 2 and 3). (5) Eligible 
to enter study as a treated participant: FP/SAL treatment (re)starts, patient can be selected as a treated study participant on 
the date that FP/SAL treatment (re)starts. This is the second treated period that this person can contribute to the total pool of 
treated period records that will be available for propensity score matching to the untreated participants (as detailed in steps 
4–6). COPD, chronic obstructive pulmonary disease;  CPRD, UK Clinical Practice Research Datalink; FEV1, forced expiratory 
volume in 1 s; FP/ SAL,  fluticasone  propionate+salmeterol; FVC, forced vital capacity. 
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Step 3
Having obtained individual-level patient data for TORCH 
participants from  clin ical stud ydat areq uest. com, we will 
then match each TORCH participant (n=6112) 1:1 with 
the closest available unexposed patient record in the 
CPRD pool of FP/SAL untreated patients obtained in 
step 2. Matching will be based on the following TORCH 
baseline characteristics:
 ► age
 ► sex
 ► body mass index
 ► previous treatment with:
 – inhaled corticosteroids
 – LABA
 ► history of COPD exacerbations
 ► history of cardiovascular disease
 ► lung function.
Where an individual from CPRD has multiple unex-
posed ‘eligibility periods’ that can be matched to a 
TORCH participant, the CPRD characteristics that will 
be matched on will be those from the beginning of the 
specific eligibility period.
Some of the TORCH inclusion criteria will not be 
fully assessable using CPRD data (eg, we will be able to 
assess whether patients are smokers but will not always 
know their pack year history). Hence, the inclusion/
exclusion criteria are analogous with TORCH criteria 
but we acknowledge they are not identical. Identifica-
tion of criteria will be done based on algorithms already 
determined and by the identification of clinical codes in 
the CPRD. For those individuals that have contributed 
multiple unexposed records to the pool of CPRD unex-
posed participants (figure 3), after one of their unex-
posed records has been matched to a TORCH participant 
we will remove all of their other unexposed records 
(meaning that an individual can only appear once in the 
final TORCH-matched unexposed cohort). We anticipate 
matching all or the majority of TORCH participants with 
a CPRD patient, giving us a pool of TORCH-analogous 
untreated patients within CPRD, with similar baseline 
characteristics as TORCH participants at the point of 
randomisation (n~6000, figure 2).
Step 4
Following this, we will select all patients in CPRD meeting 
the TORCH eligibility criteria specified above, and who 
also received treatment with FP/SAL (either on the date 
of eligibility or at a later date). From feasibility work, 
we anticipate ~12 000 eligible FP/SAL-treated patients 
(figure 2), some of whom may have multiple time periods 
of treated patient eligibility and therefore could contribute 
more than once to the initial pool of treated patients 
(figure 3). In contrast to the unexposed TORCH-eligible 
cohort, our initial approach will not involve matching 
participants of the exposed (to FP/SAL) TORCH-eligible 
cohort with participants from the TORCH trial, as this 
would negatively impact the ability to calculate propen-
sity scores for receiving FP/SAL in step 5. Note that there 
will be overlap between those selected as untreated (in 
step 2) and as treated (in step 4). Approximately 90% of 
the step 4 treated patients will also have been eligible as 
step 2 untreated patients, as they will have had periods 
where they were not treated with FP/SAL and met the 
step 2 untreated eligibility criteria in addition to separate 
periods where they were treated with FP/SAL and met 
the step 4 treated eligibility criteria (figure 3). If a person 
is included in both the untreated step 2 and treated step 
4 cohorts, they will be contributing different periods of 
their person-time to each cohort (pre-FP/SAL treatment 
for step 2 vs post-FP/SAL treatment for step 4), and this 
will be handled in the analysis by assigning different index 
dates for step 2 compared with step 4.
Step 5
We will combine the CPRD groups obtained in steps 
3 and 4 (n~18 000, see note in step 4 relating to 90% 
overlap) and using their baseline characteristics will 
calculate propensity scores for receiving FP/SAL. The 
propensity score calculation will be based on a wide range 
of covariates (see the 'Statistical analysis' section for full 
details). Where a participant is contributing more than 
one treated time period record to the pool of exposed 
records (as described in step 4), baseline characteristics 
will be updated at the beginning of each treatment-eli-
gible period. Multiple eligible treatment periods from a 
single person are then included in the propensity score 
model as if they came from different individuals. The vari-
ables selected for the score will then become the basis for 
propensity score modelling in objectives 2 and 3.
Step 6
Each untreated patient derived in step 3 (n~6000) will 
be matched 1:1 with the FP/SAL-treated patient record 
from step 4 with the closest propensity score (~12 000) 
giving us an analysis population for objective 1 of ~12 000 
patients—double the size of TORCH (figure 2). For 
those individuals that have contributed multiple exposed 
records to the pool of CPRD-exposed participants 
(figure 3), after one of their exposed records has been 
propensity-score matched to an unexposed participant, 
we will remove all other exposed records for that indi-
vidual from the remaining pool of CPRD-exposed partic-
ipants. This will mean that an individual can only appear 
once as an exposed participant in the final propensi-
ty-score matched cohort.
We will also apply an alternative additional approach 
for objective 1, where instead of generating and using 
propensity scores to obtain a final analysis population at 
steps 5 and 6, we will match records from our exposed 
TORCH-eligible cohort with participants from the 
TORCH trial to create a TORCH-analogous exposed 
patient cohort. This will then be combined with the 
TORCH-analogous unexposed patient cohort to create 
a final analysis population (with multivariable regression 
techniques used to account for confounding instead of 
propensity scores). 
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Objective 2: measurement of COPD treatment effects in patients 
excluded from trials
We will select separate cohorts of patients who have a 
valid COPD diagnosis in the CPRD8 and who would not 
have been eligible for inclusion in the TORCH trial (and 
therefore also not eligible for our objective 1) due to the 
following characteristics: (1) age >80 years OR (2) history 
of lung surgery OR (3) history of long-term oxygen 
therapy OR (4) evidence of drug/alcohol abuse OR (4) 
an asthma diagnosis at any time prior to inclusion OR (5) 
substantial comorbidity. In relation to substantial comor-
bidity, TORCH required people to be excluded from 
the trial if they had serious uncontrolled disease with a 
likelihood of causing death within 3 years. It is likely this 
criterion affected participant selection and led to a lower 
overall rate of death than originally anticipated, although 
we recognise this criterion is subjective. During objective 
1, we will be able to select groups of people who were 
generally not included despite being eligible, most likely 
because of this subjective exclusion criterion. We antic-
ipate this will be people with substantial comorbidity, 
for example, serious vascular disease. Status for such 
diseases is readily identified in both the CPRD data and in 
the TORCH baseline data. We will only be able to specify 
this criterion in detail after we have completed objective 
1.
Participants for each of the objective 2 cohorts will be 
selected in a similar fashion to the objective 1 cohort, with 
the amended eligibility criteria specified above applied 
(ie, step 1 will be modified for selection of each of the 
objective 2 cohorts). As for objective 1, each participant 
will be allowed to have multiple FP/SAL exposed and 
unexposed eligibility periods in their record, as described 
in figure 3. In contrast to objective 1, there will be no 
matching of unexposed patients to TORCH patients, as 
we do not require a TORCH-analagous cohort for this 
analysis (ie, no step 3). All other selection steps will be 
as applied for objective 1, including the use of propen-
sity score matching in order to obtain comparable unex-
posed and exposed groups for analysis.
Objective 3: determination of treatment effects in an understudied 
disease stage
We will select separate cohorts of patients who have 
a valid COPD diagnosis in the CPRD8 and who would 
not have been eligible for inclusion in the TORCH 
trial (or our objective 1) due to the following char-
acteristics: (1) >60% predicted FEV1 (or >50% plus 
Medical Research Council breathlessness scale 1 or 2, 
or >50% plus COPD Assessment Test score <10) and (2) 
no exacerbations in the year post-COPD diagnosis. We 
will also perform a sensitivity analysis where we allow the 
group of people with FEV1 >60% predicted who had a 
maximum of one exacerbation within 1 year post-COPD 
diagnosis to be included. As for objective 2, the selection 
steps will be similar to objective 1, with modified criteria 
for step 1 and the removal of the TORCH-matching step 
(step 3).
Exposures, outcomes and covariates
Exposures
For all objectives, exposures will be determined using 
CPRD prescribing records and code lists for COPD 
treatments (codelists provided in online supplementary 
material).
For objective 1, use of FP/SAL (trade name Seretide) 
is the primary exposure of interest and will be compared 
with no treatment with FP/SAL. We will limit included 
patients to those receiving Seretide 500/50, the dose used 
in TORCH. This information is recorded for all prescrip-
tions of Seretide and this dose is the only currently 
approved dose for COPD in the UK (although we recog-
nise some prescribing may not follow the licensed indica-
tion). If the results for our FP/SAL versus no treatment 
comparison are not consistent with the TORCH FP/SAL 
versus placebo results (see the 'Statistical analysis' and 
'Validation of results against TORCH' sections for a defi-
nition of consistent), we will perform additional analyses 
where instead of using a no-treatment comparator group, 
our objective 1 comparator group will be people exposed 
to SAL, one of the other comparator groups from the 
TORCH trial.
As a secondary analysis in objective 1, other treatments 
for COPD will also be compared with no treatment. Selec-
tion of unexposed and exposed people for each of these 
drugs will follow steps 1–6 detailed above in the 'Selection 
of participants—objective 1' section, although step 3 will 
be omitted (as these cohorts will not need to be matched 
to TORCH). The other treatments we plan to include are 
as follows:
a. LABA
b. LAMA
c. LABA+LAMA 
d. LABA+ICS other than FP/SAL
e. LABA+LAMA+ICS.
For objectives 2 and 3, we will again use recorded 
prescribing information to determine the dose received. 
We will be reliant mostly on the strength of each indi-
vidual drug, which is recorded automatically against each 
product and does not require general practitioners (GPs) 
to enter these data, ensuring completeness. We will then 
be able to stratify analyses based on the dose prescribed. 
Specific exposures for objectives 2 and 3 are as follows (all 
vs no treatment):
a. FP/SAL
b. LABA
c. LAMA
d. LABA+LAMA 
e. LABA+ICS 
f. LABA+LAMA+ICS.
Outcomes
Outcomes to be measured are as follows:
1. COPD exacerbation: to be defined using a CPRD-HES 
algorithm developed previously by authors of this 
study protocol.10
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2. All-cause mortality: as recorded in Office of National 
Statistics (ONS) mortality statistics (data that is linked 
to CPRD data).
3. Pneumonia: as defined using a CPRD-HES algorithm 
published previously by authors of this study proto-
col.11
4. Time to COPD treatment change: determined by pre-
scribing records indicating the start of a new, addi-
tional COPD treatment.
Covariates
Covariates to be considered for inclusion in the propen-
sity score include the following (all obtained from CPRD 
data):
 ► Lung function (FEV1, FEV1/FVC)
 ► Age
 ► Gender
 ► Body mass index
 ► Alcohol consumption
 ► Vascular disease (broken into individual compo-
nents, eg, hypertension, heart failure, atherosclerotic 
disease)
 ► Use of prescribed aspirin and statins
 ► Prior treatment with other COPD medication
 ► Type 2 diabetes
 ► History of cancer
 ► Renal disease
 ► Healthcare utilisation intensity (number of prior 
visits, hospitalisations, number of distinct medications 
used, number of procedures).
sample size
Objective 1
Assuming a baseline conservative exacerbation rate of 0.5 
per patient per year,10 we would only require a sample 
of 408 patients per treatment group to detect a reduc-
tion in annual exacerbation rate to 0.4 per year, with 80% 
power and 5% significance. The estimated sample size 
is ~12 000, which will provide ample power for the main 
outcomes of interest, and allow stratification by patient 
characteristics to determine stratified results, and will 
also be ample for the secondary analyses where we will 
use 99% CIs. For example, to detect a reduction from 0.5 
to 0.4 exacerbations per year with 80% power and 1% 
significance we would need ~600 people in each treat-
ment group.
Objectives 2 and 3
We are also confident that we will have sufficient numbers 
to allow well-powered analyses for objectives 2 and 3. For 
example, a feasibility count looking at the number of 
people over the age of 80 eligible for inclusion in objec-
tive 2 estimated that there would be >2000 people in each 
exposure group.
statistical analysis
Propensity score for addressing confounding
The propensity score will be constructed using the prin-
ciple that predictors of the exposure and outcome, or 
outcome only (mortality) should be included. We will 
consider a wide range of factors for inclusion (as listed 
in the 'Covariates' section), such as: age, sex, body mass 
index, alcohol consumption and a wide range of comor-
bidities (eg, type 2 diabetes, coronary heart disease, cere-
brovascular disease, peripheral vascular disease, heart 
failure, hypertension, renal disease, cancer). We will 
further adjust for healthcare utilisation intensity (number 
of prior visits, hospitalisations, number of distinct medi-
cations used, number of procedures, etc) as these are 
generic correlates of disease state and the likelihood of 
recording completeness. We have substantial prior expe-
rience of building propensity models.13–16
For the additional alternative approach to objective 
1 relying on matching of both unexposed and exposed 
patients to the TORCH trial patients (described in 
the 'Selection of participants—objective 1—step 
6' section), we will use multivariable regression tech-
niques to address confounding, considering a similar 
wide range of covariates for adjustment.
The variable list used for the propensity score model 
obtained in objective 1 will be the basis for propensity 
score modelling in objectives 2 and 3, but additional vari-
ables will also be considered given the different nature of 
the patient populations being studied in these objectives.
Methods of analysis
For all objectives, comparisons will be made according 
to FP/SAL (or other drugs being analysed as specified 
in the 'Exposures' section) status for rate of COPD exac-
erbation, pneumonia and mortality over 3 years. All 
analyses will be performed according to the ‘intention-
to-treat’ principle (as was done in the TORCH study), 
meaning that if a participant enters the study as either 
an exposed or unexposed participant, they will remain 
assigned to that exposure category for the entire dura-
tion of their follow-up (irrespective as to whether their 
true exposure status changes). For exacerbations, a 
negative binomial model will be used, accounting 
for variability between patients in the number and 
frequency of exacerbations, with the number of exac-
erbations as the outcome and the log of treated time as 
an offset variable. Time to mortality, first pneumonia 
and treatment change will be analysed using Cox 
proportional hazards regression. This mirrors TORCH 
end points of major benefit and harm. We anticipate the 
propensity matching process will allow us to assemble 
treated and untreated groups that are very similar with 
respect to baseline characteristics except FP/SAL treat-
ment status. However, this will be tested by assessing 
standardised differences for each baseline variable. If 
substantial differences are noted for important vari-
ables, it may be necessary to further adjust the statistical 
models. This could also include examining the effect of 
using greedy versus optimum matching approaches in 
order to obtain the closest propensity score match and/
or matching at a ratio other than 1:1.17
group.bmj.com on April 5, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
9Wing K, et al. BMJ Open 2018;8:e019475. doi:10.1136/bmjopen-2017-019475
Open Access
Validation of results against TORCH
We will validate our findings against TORCH as part of 
objective 1 by determining whether results of the CPRD 
FP/SAL versus no FP/SAL treatment analysis are compat-
ible with the TORCH exacerbations rate ratio for FP/SAL 
versus placebo (0.75; 95% CI 0.69 to 0.81). This outcome 
has been selected as it is an outcome of key significance 
for people with COPD4 and the result in TORCH shows 
a clear benefit with 95% confidence limits below 1. We 
have set two criteria that must be met for us to conclude 
results are consistent. First, the effect size must be clin-
ically comparable with TORCH findings; the rate ratio 
for exacerbations in CPRD must be between 0.65 and 
0.9. This range is deliberately not symmetrical around 
the TORCH estimate of 0.75 as we would anticipate the 
treatment effect in routine clinical care may be weaker 
than that seen in the optimised setting of a randomised 
trial. We recognise this rule could be met with a poorly 
powered, inconclusive result, so a second criterion is that 
the 95% CI for the rate ratio must exclude 1. If we go 
on to compare FP/SAL with SAL alone (see the 'Expo-
sures, outcomes and covariates' section, 'Exposures' 
subheading), the 95% CI would also need to exclude 1, 
and the rate ratio would need to be between 0.81 and 
0.95 (compared with the TORCH FP/SAL vs SAL result 
of 0.88, 95% CI 0.81 to 0.95).
Handling measurement of adherence to medication
Adherence to issued prescribing in general practice 
is likely to vary according to the treatment issued, for 
example, short course antibiotic treatment is notoriously 
not well adhered to, whereas long-term life-saving treat-
ment such as antiretroviral medication is more likely to 
be taken as prescribed. While we do not have figures for 
adherence for COPD medication in UK general practice, 
we are able to estimate the proportion of time covered by 
prescribing as a proxy for adherence and will account for 
this in our analyses. Moreover, our intention is to estimate 
the effect of prescribing at the population level, and to 
some extent, the clinical effects we will measure are in 
part due to pharmacological effects, and in part the way 
the treatment is taken which includes adherence. Also of 
note, prescribing for COPD in the UK is predominantly 
through GPs and so we will not be missing prescribing 
information from other potential sources of treatment.
The data analysis for adherence will necessarily be a 
significant element of the work to be done for this study. 
However, we have reviewed the records for a random 
sample of 30 people with COPD starting treatment with 
FP/SAL to look at adherence patterns over the course of 
a year. Of the 30 patients, 20 (67%) were still receiving 
Seretide (FP/SAL) 1 year after starting treatment. Of the 
20 who received Seretide for a full year, 15 (75%) received 
sufficient prescriptions to suggest at least 50% adherence 
over the year and 8 (40%) had sufficient prescriptions 
to suggest 80% adherence or higher. As expected, this 
suggests two things: first, adherence is likely to be poorer 
in routine clinical care than in the trial population; in 
TORCH 80% of participants were estimated to have 
adherence at 80% or higher. Second, there is a wide 
range of adherence in routine care. This will allow us to 
estimate both the population-level effects of treatment as 
actually used in routine care and to estimate the treat-
ment effect in patients with more similar levels of adher-
ence to TORCH participants. While we acknowledge that 
prescribing can only be a proxy for used medication, we 
believe it is not an unreasonable assumption that the 
amount of medication prescribed is correlated with the 
amount consumed. We plan to assess adherence for the 
cohort that we select for objective 1 beyond 1 year and 
report the findings. In the event that objective 1 detects 
a null or poorer treatment effect than anticipated (rate 
ratio >0.9), we will conduct a sensitivity analysis restricted 
to people estimated to be covered by FP/SAL treatment 
for 80% of their follow-up.
Misclassification of drug exposure periods and outcome status
It is possible that an individual may still be exposed to 
FP/SAL for some time after a prescription has finished, 
for example, if they have medication at home that they 
have not used from a previous prescription. This would 
mean that people may become eligible for inclusion in 
the unexposed group while they are actually still exposed. 
If our result differs from the TORCH results (eg, a rate 
ratio <0.65 or >0.9), we will conduct a sensitivity anal-
ysis in which we include an additional (grace) exposed 
period equivalent to the length of a single prescription at 
the end of each actual exposed period, and only classify 
individuals as eligible for inclusion as unexposed at the 
end of this additional period.
Our results could also be impacted by misclassification 
of outcome, given the routine nature of the data. Our 
initial approach for detection of COPD exacerbations is 
to use a validated case definition from previous work that 
maximises positive predictive value while maintaining a 
relatively high sensitivity.12 If our result differs from the 
TORCH results, we will consider performing a sensi-
tivity analysis in which we assess the impact of applying 
alternative case definitions for COPD exacerbations (see 
online supplementary material for an overview of articles 
relating to the case definitions we plan to use, including 
any validity measurements provided).
Missing data
CPRD data are shown to be almost complete for drug 
prescribing and mortality (partly through ONS linkage). 
Smoking history tends to be very well recorded for 
people with COPD and missingness is likely to be 
minimal.10 Information on important comorbidity is also 
well recorded in CPRD. We will conduct both complete 
record analyses and use multiple imputation where 
appropriate assumptions hold, applying findings from 
methodological work led by one of the study team (EW) 
into the use of multiple imputation in propensity score 
modelling.16
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EthICs And dIssEMInAtIon
Approval by ethics and scientific committees
An application for scientific approval related to use of 
the CPRD data has been approved by the Independent 
Scientific Advisory Committee of the Medicines and 
Healthcare Products Regulatory Agency (protocol no. 
17_114R). CPRD data are already approved via a National 
Research Ethics Committee for purely non-interventional 
research of this type.
An application for use of the TORCH trial individual 
patient data was made to the  cli nica lstu dyda tare quest. com 
site, which is checked by the Wellcome Trust and relevant 
sponsors to make sure information is complete and that 
the sponsor’s requirements for informed consent have 
been met. The application is then sent to an independent 
review panel that consider the scientific rationale, objec-
tives, publication plan, conflicts of interest and qualifica-
tions and experience of the research team before making 
a decision on providing access to the data. We recently 
obtained approval of all aspects of this application.
dissemination plans
Dissemination of findings will be via a combination of 
channels. The work will be published in high ranking 
peer-reviewed journals and we anticipate three publica-
tions to arise directly from the planned work. Findings 
will also be presented at relevant scientific conferences 
such as the British Thoracic Society Conference and the 
European Respiratory Society International Congress. We 
will also engage with patients already identified from a 
clinic run by one of the authors of this protocol (JQ) and 
from Breathe Easy Groups and with relevant charities such 
as the British Lung Foundation to determine the most 
relevant ways to disseminate results directly to patients in 
an accessible manner, and to help our understanding of 
the likely impact of results to specific groups of patients. 
We will communicate directly with the National Institute 
for Health and Care Excellence to ensure they are kept 
informed of results that are of direct relevance to the 
guidance they have issued on COPD, and with the Medi-
cines and Healthcare Products Regulatory Agency if it 
appears that findings may impact the risk/benefit profile 
of COPD treatments.
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